Sionna Therapeutics (NASDAQ:SION) Stock Price Up 8.1% – Here’s Why

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) rose 8.1% on Wednesday . The company traded as high as $39.89 and last traded at $39.78. Approximately 80,230 shares were traded during trading, a decline of 73% from the average daily volume of 298,882 shares. The stock had previously closed at $36.81.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. BTIG Research reissued a “buy” rating and issued a $58.00 price target on shares of Sionna Therapeutics in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Lifesci Capital initiated coverage on shares of Sionna Therapeutics in a report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.43.

Sionna Therapeutics Price Performance

The firm’s fifty day moving average is $40.46 and its two-hundred day moving average is $30.43. The firm has a market capitalization of $1.78 billion and a PE ratio of -8.21.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insider Buying and Selling at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 33,356 shares of Sionna Therapeutics stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the sale, the director directly owned 3,561,655 shares in the company, valued at $158,671,730.25. The trade was a 0.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Peter A. Thompson sold 33,356 shares of the business’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the completion of the transaction, the director directly owned 3,561,655 shares in the company, valued at $158,671,730.25. This trade represents a 0.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 1,312,357 shares of company stock valued at $50,469,863. Insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SION. Bank of America Corp DE lifted its position in shares of Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after acquiring an additional 529 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Sionna Therapeutics by 35.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock valued at $70,000 after purchasing an additional 619 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics during the 3rd quarter valued at $30,000. Police & Firemen s Retirement System of New Jersey bought a new position in Sionna Therapeutics in the 2nd quarter worth about $45,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Sionna Therapeutics by 13.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,038 shares of the company’s stock worth $660,000 after purchasing an additional 4,489 shares during the period.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.